[1]
|
Zhang, B.H., Yang, B.H. and Tang, Z.Y. (2004) Randomized Controlled Trial of Screening for Hepatocellular Carcinoma. Journal of Cancer Research & Clinical Oncology, 130, 417-422. https://doi.org/10.1007/s00432-004-0552-0
|
[2]
|
Galle, P.R., Forner, A., Llovet, J.M., et al. (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236. https://doi.org/10.1016/j.jhep.2018.03.019
|
[3]
|
Zhou, M., Wang, H., Zeng, X., et al. (2013) Mortality, Morbidity, and Risk Factors in China and Its Provinces, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 394, 1145-1158.
https://doi.org/10.1016/S0140-6736(19)30427-1
|
[4]
|
Allemani, C., Weir, H.K., Carreira, H., et al. (2013) Global Surveillance of Cancer Survival 1995-2009: Analysis of Individual Data for 25676887 Patients from 279 Population-Based Registries in 67 Countries (CONCORD-2). The Lancet, 385, 977-1010. https://doi.org/10.1016/S0140-6736(14)62038-9
|
[5]
|
Torre, L.A., Bray, F., Siegel, R.L., et al. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108. https://doi.org/10.3322/caac.21262
|
[6]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[7]
|
苏敬博, 张健, 金哲川, 等. 《2020年NCCN肝胆肿瘤临床实践指南(V1版)》胆管癌诊治进展解读[J]. 西部医学, 2020, 32(7): 946-952.
|
[8]
|
Kulik, L. and El-Serag, H.B. (2019) Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 156, 477-491. https://doi.org/10.1053/j.gastro.2018.08.065
|
[9]
|
Ishida, Y., Agata, Y., Shibahara, K., et al. (1992) Induced Expression of PD a Novel Member of the Immunoglobulin Gene Superfamily, upon Programmed Cell Death. The EMBO Journal, 11, 3887-3895.
https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
|
[10]
|
Larsson, M., Shankar, E.M., Che, K.F., et al. (2013) Molecular Signatures of T-Cell Inhibition in HIV-1 Infection. Retrovirology, 10, 31. https://doi.org/10.1186/1742-4690-10-31
|
[11]
|
Dong, H., Zhu, G., Tamada, K., et al. (1999) B7-H1, a Third Member of the B7 Family, Co-Stimulates T-Cell Proliferation and Interleukin-10 Secretion. Nature Medicine, 5, 1365-1369. https://doi.org/10.1038/70932
|
[12]
|
Dong, H.D., et al. (2002) Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nature Medicine, 8, 793-800. https://doi.org/10.1038/nm730
|
[13]
|
Mcdermott, D.F. and Atkins, M.B. (2013) PD-1 as a Potential Target in Cancer Therapy. Cancer Medicine, 2, 662-673.
https://doi.org/10.1002/cam4.106
|
[14]
|
Zou, W. and Chen, L. (2008) Inhibitory B7-Family Molecules in the Tumour Microenvironment. Nature Reviews Immunology, 8, 467-477. https://doi.org/10.1038/nri2326
|
[15]
|
Balar, A.V. and Weber, J.S. (2017) PD-1 and PD-L1 Antibodies in Cancer: Current Status and Future Directions. Cancer Immunology and Immunotherapy, 66, 551-564. https://doi.org/10.1007/s00262-017-1954-6
|
[16]
|
Marginean, E.C. and Melosky, B. (2017) Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer with Microsatellite Instability? Part I, Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Archives of Pathology & Laboratory Medicine, 142, 17-25.
https://doi.org/10.5858/arpa.2017-0040-RA
|
[17]
|
Stein, S., Pishvaian, M.J., Lee, M.S., et al. (2018) Safety and Clinical Activity of 1L Atezolizumab + Bevacizumab in a Phase Ib Study in Hepatocellular Carcinoma (HCC). Journal of Clinical Oncology, 36, 4074-4074.
https://doi.org/10.1200/JCO.2018.36.15_suppl.4074
|
[18]
|
Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382, 1894-1905. https://doi.org/10.1056/NEJMoa1915745
|
[19]
|
Cheng, A.L., Qin, S., Ikeda, M., et al. (2019) IMbrave150: Efficacy and Safety Results from a ph III Study Evaluating Atezolizumab (atezo) + Bevacizumab (bev) vs Sorafenib (Sor) as First Treatment (tx) for Patients (pts) with Unresectable Hepatocellular Carcinoma (HCC). Annals of Oncology, 30, ix186-ix187.
https://doi.org/10.1093/annonc/mdz446.002
|
[20]
|
Llovet, J., Shepard, K.V., Finn, R.S., et al. (2019) A Phase Ib Trial of Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) in Unresectable Hepatocellular Carcinoma (uHCC): Updated Results. Annals of Oncology, 30, v286-v287.
https://doi.org/10.1093/annonc/mdz247.073
|
[21]
|
Qin, S., Chen, Z., Liu, Y., et al. (2019) A Phase II Study of Anti-PD-1 Antibody Camrelizumab plus FOLFOX4 or GEMOX Systemic Chemotherapy as First-Line Therapy for Advanced Hepatocellular Carcinoma or Biliary Tract Cancer. Journal of Clinical Oncology, 37, 4074. https://doi.org/10.1200/JCO.2019.37.15_suppl.4074
|
[22]
|
李嘉祺. 阿帕替尼联合卡瑞利珠单抗治疗晚期肝细胞癌的临床观察[D]: [硕士学位论文]. 大理: 大理大学, 2021.
|
[23]
|
Ds, A., Paa, B., Jh, C., et al. (2019) Safety and Efficacy of Nivolumab in Challenging Subgroups with Advanced Melanoma Who Progressed on or after Ipilimumab Treatment: A Single-Arm, Open-Label, Phase II Study (CheckMate 172). European Journal of Cancer, 121, 144-153. https://doi.org/10.1016/j.ejca.2019.08.014
|
[24]
|
Horn, L., Spigel, D.R., Vokes, E.E., et al. (2017) Nivolumab versus Docetaxel in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes from Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35, 3924-3933. https://doi.org/10.1200/JCO.2017.74.3062
|
[25]
|
Ramchandren, R., Domingo-Domènech, E., Ru Eda, A., et al. (2019) Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. Journal of Clinical Oncology, 37, 1997-2007. https://doi.org/10.1200/JCO.19.00315
|
[26]
|
Harrington, K.J., Ferris, R.L., Blumenschein, G., et al. (2017) Nivolumab versus Standard, Single-Agent Therapy of Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 141): Health-Related Quality-of-Life Results from a Randomised, Phase 3 Trial. The Lancet Oncology, 18, 1104-1115.
https://doi.org/10.1016/S1470-2045(17)30421-7
|
[27]
|
Todd, C., Tim, M., Ignacio, M., et al. (2018) Tu1483—Hepatic Safety and Biomarker Assessments in Sorafenibexperienced Patients with Advanced Hepatocellular Carcinoma Treated with Nivolumab in the Checkmate-040 Study. Gastroenterology, 154, S-1234. https://doi.org/10.1016/S0016-5085(18)34061-7
|
[28]
|
El-Khoueiry, A.B. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase? Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502.
https://doi.org/10.1016/S0140-6736(17)31046-2
|
[29]
|
Yau, T., Park, J.W., Finn, R.S., et al. (2019) CheckMate 459: A Randomized, Multi-Center Phase III Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) with Advanced Hepatocellular Carcinoma (aHCC). Annals of Oncology, 30, v874-v875. https://doi.org/10.1093/annonc/mdz394.029
|
[30]
|
Zhu, A.X., Finn, R.S., Julien, E., et al. (2019) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. The Lancet. Oncology, 19, 940-952.
|
[31]
|
Finn, R.S., Ryoo, B.Y., Merle, P., et al. (2019) Results of KEYNOTE-240: Phase 3 Study of Pembrolizumab (Pembro) vs Best Supportive Care (BSC) for Second Line Therapy in Advanced Hepatocellular Carcinoma (HCC). Journal of Clinical Oncology, 37, 4004. https://doi.org/10.1200/JCO.2019.37.15_suppl.4004
|
[32]
|
Nie, J., Wang, C., Liu, Y., et al. (2019) Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 37, 1479-1489.
https://doi.org/10.1200/JCO.18.02151
|
[33]
|
Qin, S.K., Ren, Z.G., Meng, Z.Q., et al. (2018) LBA27A Randomized Multicentered Phase II Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Failed or Intolerable to Prior Systemic Treatment. Annals of Oncology, 29, VIII719-VIII720. https://doi.org/10.1093/annonc/mdy424.029
|
[34]
|
Xu, J., Zhang, Y., Jia, R., et al. (2013) Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-Label, Dose Escalation and Expansion Study. Clinical Cancer Research, 25, 515-523. https://doi.org/10.1158/1078-0432.CCR-18-2484
|
[35]
|
Bang, Y.J., Goff, L.W., Wasserstrom, H., et al. (2016) An Open-Label, Multicenter, Phase 1 Study of Ramucirumab (R) plus Durvalumab (D) in Patients (pts) with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), or Hepa. Annals of Oncology, 27, VI376. https://doi.org/10.1093/annonc/mdw378.53
|
[36]
|
He, A.R., Yau, T., Hsu, C., et al. (2020) Nivolumab (NIVO) + Ipilimumab (IPI) Combination Therapy in Patients (pts) with Advanced Hepatocellular Carcinoma (aHCC): Subgroup Analyses from CheckMate 040. Journal of Clinical Oncology, 38, 512. https://doi.org/10.1200/JCO.2020.38.4_suppl.512
|
[37]
|
Fukumura, D., Kloepper, J., Amoozgar, Z., et al. (2018) Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges. Nature Reviews Clinical Oncology, 15, 325-340.
https://doi.org/10.1038/nrclinonc.2018.29
|